[Comment] Is PORTEC-4a the tipping point in endometrial cancer management?

The PORTEC-4a trial1 provides, to the best of our knowledge, the first prospective, randomised evidence that a molecular integrated risk profile can safely guide adjuvant therapy decisions in high-intermediate risk endometrial cancer, reinforcing the rationale for incorporating molecular classification into clinical practice. According to Anne Sophie V M van den Heerik and colleagues’ findings in the Lancet Oncology,2 a refined molecular stratification supports a more tailored adjuvant treatment, enabling either de-escalation or intensification of radiotherapy based on individual tumour biology.